Interactions among ACE, kinins and NO

Cardiovascular Research

Volumn 43, Issue 3, 1999, Pages 549-561

  Linz, Wolfgang ^a   Wohlfart, Paulus ^a   Schölkens, Bernward A ^a   Malinski, Tadeusz ^b   Wiemer, Gabriele ^a  

^a SANOFI   (France)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

ACE; Kinins; NO; Superoxide

Indexed keywords

ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KININ; NITRIC OXIDE; RAMIPRIL;

BIODEGRADATION; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME REGULATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW;

EID: 0033566604     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00091-7     Document Type: Review

References (184)

1. Gohlke P., Bünning P., Unger T. Distribution and metabolism of angiotensin I and II in the blood vessel wall. Hypertension. 20:1992;151-157.
2. Arnal J.F., Battle T., Rasetti C., et al. ACE in three tunicae of rat aorta: expression in smooth muscle and effect of renovascular hypertension. Am J Physiol. 267:(Heart Circ Physiol 36):1994;H1777-H1784.
3. Erdös E.G. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol. 15:(Suppl 6):1990;S20-S24.
4. Bhoola K.D., Figueroa C.D., Worthy K. Bioregulation of kinins, kallikreins, kininogens, and kininases. Pharmacol Rev. 44:1992;1-80.
5. Mombouli J.-V., Vanhoutte P.M. Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol. 35:1996;679-705.
6. Wiemer G., Schölkens B.A., Becker R.H.A., Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 18:1991;558-563.
7. Moro M.A., Russel R.J., Cellek S., et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci. 93:1996;1480-1485.
8. Papapetropoulos A., Cziraki A., Rubin J.W., Stone C.D., Catravas J.D. cGMP accumulation and gene expression of soluble guanylate cyclase in human vascular tissue. J Cell Physiol. 167:1996;213-221.
9. Flesch M., Kilter H., Cremers B., et al. Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J Pharmacol Exper Ther. 281:1997;1340-1349.
10. Brady A.J.B., Warren J.B., Poole-Wilson P.A., Williams T.J., Harding S.E. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol. 265:(Heart Circ Physiol 34):1993;H176-H182.
11. Evans H., Smith J.A., Lewis M.J. Release of endothelium-derived relaxing factor is inhibited by 8-bromo-cyclic guanosine-monophosphate. J Cardiovasc Pharmacol. 12:1988;672-677.
12. Martin W., White D.G., Henderson A.H. Endothelium-derived relaxing factor and atriopeptin II elevate cyclic GMP levels in pig aortic endothelial cells. Br J Pharmacol. 93:1988;229-239.
13. Linz W., Wiemer G., Gohlke P., Unger T., Schölkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 47:1995;25-49.
14. Hornig B., Kohler C., Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 95:1997;1115-1118.
15. G-nitro-L-arginine methyl ester due to converting enzyme inhibition. J Cardiovasc Pharmacol. 28:1996;142-148.
16. Takemoto M., Egashira K., Usui M., et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest. 99:1997;278-287.
17. Ackermann A., Fernandez-Alfonso M.S., Sanchez de Rojas R., et al. Modulation of angiotensin-converting enzyme by nitric oxide. Br J Pharmacol. 124:1998;291-298.
18. Linz W., Jessen T., Becker R.H.A., Schölkens B.A., Wiemer G. Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation. 96:1997;3164-3172.
19. Wiemer G., Linz W., Hatrik S., Schölkens B.A., Malinski T. Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. Hypertension. 30:1997;1183-1190.
20. Saijonmaa O., Fyrquist F. Upregulation of angiotensin converting enzyme by atrial natriuretic peptide and cyclic GMP in human endothelial cells. Cardiovasc Res. 40:1998;206-210.
21. Linz W., Wiemer G., Schölkens B.A. ACE-inhibition induces NO-formation in cultured bovine aortic endothelial cells and protects isolated ischaemic rat hearts. J Mol Cell Cardiol. 24:1992;909-919.
22. Parratt J.R. Cardioprotection by angiotensin converting enzyme inhibitors - the experimental evidence. Cardiovasc Res. 28:1994;183-189.
23. Liu Y.-H., Yang X.-P., Sharov V.G., et al. Paracrine systems in the cardioprotective effect of angiotensin converting enzyme inhibitors on myocardial ischaemia/reperfusion injury in rats. Hypertension. 27:1996;7-13.
24. Busse R., Fleming I., Hecker M. Endothelium-derived bradykinin: Implications for angiotensin-converting enzyme-inhibitor therapy. J Cardiovasc Pharmcol. 22:(Suppl 5):1993;S31-S36.
25. Kichuk M.R., Seyedi N., Zhang X., et al. Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation. Circulation. 94:1996;44-51.
26. Brotherton A.F.A. Induction of prostacyclin biosynthesis is closely associated with guanosine 3′,5′-cyclic monophosphate accumulation in cultured human endothelium. J Clin Invest. 78:1986;1253-1260.
27. 2 kinin receptors in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther. 252:1990;581-585.
28. 1 kinin receptor expression and pharmacology in endothelial cells of different origins and species. J Pharmacol Exper Ther. 280:1997;1109-1116.
29. Wiemer G., Pierchala B., Mesaros S., Schölkens B.A., Malinski T. Direct measurement of nitric oxide release from cultured endothelial cells stimulated by bradykinin or ramiprilat. Endothelium. 4:1996;119-125.
30. Inoue N., Venema R.C., Sayegh H.S., et al. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-β1. Arterioscler Throm Vasc Biol. 15:1995;1255-1261.
31. Hecker M., Bara A.T., Busse R. Relaxation of isolated coronary arteries by angiotensin-converting enzyme inhibitors: Role of endothelium-derived kinins. J Vasc Res. 30:1993;257-262.
32. Desta B., Nakashima M., Kirchengast M., Vanhoutte P.M., Boulanger C.M. Previous exposure to bradykinin unmasks an endothelium-dependent relaxation to the converting enzyme inhibitor trandolaprilat in isolated canine coronary arteries. J Pharmacol Exp Ther. 272:1994;885-891.
33. Auch-Schwelk W., Bossaller C., Claus M., et al. ACE inhibitors are endothelium-dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res. 27:1993;312-317.
34. Auch-Schwelk W., Duske E., Claus M., et al. Endothelium-mediated vasodilation during ACE inhibition. Eur Heart J. 16:(Suppl C):1995;59-65.
35. Hecker M., Pörsti I., Bara A.T., Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br J Pharmacol. 111:1994;238-244.
36. Hecker M., Blaukat A., Bara A.T., Müller-Esterl W., Busse R. ACE inhibitor potentiation of bradykinin-induced venoconstriction. Br J Pharmacol. 121:1997;1475-1481.
37. Busse R., Lamontagne D. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells. Naunyn Schmiedeberg's Arch Pharmacol. 344:1991;126-129.
38. Hutri-Kähönen N., Pörsti I., Wu X., et al. Arterial responses to bradykinin after ramipril therapy in experimental hypertension. Pharmacol Toxicol. 81:1997;190-196.
39. 2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res. 81:1997;848-856.
40. Minshall R.D., Erdös E.G., Vogel S.M. Angiotensin I converting enzyme inhibitors potentiate bradykinins's inotropic effects independently of blocking its activation. Am J Cardiol. 80:(3A):1997;132A-136A.
41. 2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 1999;in press.
42. 2 receptor in caveolae. J Cell Sci. 111:1998;917-928.
43. Welches W.R., Brosnihan K.B., Ferrario C.M. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase. Life Sci. 52:1993;1461-1480.
44. Campbell D.J., Lawrence A.C., Towrie A., Kladis A., Valentijn A.J. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension. 18:1991;763-773.
45. Moriguchi A., Brosnihan K.B., Kumagai H., Ganten D., Ferrario C.M. Mechanism of hypertension in transgenic rats expressing the mouse Ren-2-gene. Am J Physiol. 266:1994;R1273-R1279.
46. Yamada K., Iyer S.N., Chappell M.C., Ganten D., Ferrario C.M. Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension. 32:1998;496-502.
47. Luque M., Martin P., Martell N., et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 14:1996;799-805.
48. Tran Y., Foster C. Angiotensin-(1-7) and the rat aorta: modulation by the endothelium. J Cardiovasc Pharmacol. 30:1997;676-682.
49. Pörsti I., Bara A.T., Busse R., Hecker M. Release of nitric oxide by angiotensin -(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol. 111:1994;652-654.
50. Brosnihan K.B., Li P., Ferrario C.M. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 27:(part 2):1996;523-528.
51. Gorelik G., Carbini L.A., Scicli A.G. Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J Pharmacol Exper Ther. 286:1998;403-410.
52. Tallant E.A., Lu X., Weiss R.B., Chappell M.C., Ferrario C.M. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension. 29:(part 2):1997;388-3893.
53. Paula R.D., Lima C.V., Khosla M.C., Santos R.A.S. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension. 26:(part 2):1995;1154-1159.
54. Abbas A., Gorelik G., Carbini L.A., Scicli A.G. Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension. 30:(part 1):1997;217-221.
55. Lima C.V., Paula R.D., Resende F.L., Khosla M.C., Santos A.S. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension. 30:(part 2):1997;542-548.
56. Benter I.F., Diz D.I., Ferrario C.M. Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Hypertension. 26:1995;1138-1144.
57. Oliveira D.R., Santos R.A.S., Santos G.F.P., Khosla M.C., Campagnole-Santos M.J. Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonism in hypertensive rats. Hypertension. 27:1996;1284-1290.
58. Benter I.F., Ferrario C.M., Morris M., Diz D.I. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol. 269:(Heart Circ Physiol 38):1995;H313-H319.
59. Nakamoto H., Ferrario C.M., Fuller S.B., et al. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. Hypertension. 25:1995;796-802.
60. Seyedi N., Xu X., Nasjletti A., Hintze T.H. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 26:1995;164-170.
61. Li P., Chappell M.C., Ferrario C.M., Brosnihan K.B. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 29:(part 2):1997;394-400.
62. Deddish P.A., Marcic B., Jackman H.L., et al. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme. Angiotensin-(1-7) and keto-ACE. Hypertension. 31:(1-7):1998;912-917.
63. Korth P., Fink E., Linz W., et al. Angiotensin II receptor subtype-stimulated formation of endothelial cyclic GMP and prostacyclin is accompanied by an enhanced release of endogenous kinins. Pharm Pharmacol Lett. 5:1995;124-127.
64. Wiemer G., Schölkens B.A., Busse R., et al. The functional role of angiotensin II-subtype AT2-receptors in endothelial cells and isolated ischaemic rat hearts. Pharm Pharmacol Lett. 3:1993;24-27.
65. 2 receptors in endothelial cells and isolated ischaemic rat hearts. J Hypertens. 11:(suppl 5):1993;S234-S235.
66. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 31:(part 2):1998;349-355.
67. 2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med. 4:1998;661-670.
68. 1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII. J Biol Chem. 272:1997;4245-4251.
69. Rees D.D., Palmer R.M.J., Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure (L-arginine/hypertension/vascular endothelium/endothelium-derived relaxing factor). Proc Natl Acad Sci USA. 86:1989;3375-3378.
70. Tolins J.P., Palmer R.M.J., Moncada S., Raij L. Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. Am J Physiol. 258:1990;H655-H662.
71. Moncada S., Higgs E.A. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Invest. 21:1991;361-374.
72. Bank N., Aynedjian H.S., Khan G.A. Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats. Hypertension. 24:1994;322-328.
73. Weldon S.M., Winquist R.J., Madwed J.B. Differential effects of L-NAME on blood pressure and heart rate responses to acetylcholine and bradykinin in cynomolgus primates. J Pharmacol Exper Ther. 272:1995;126-133.
74. Huang P.L., Huang Z., Mashimo H., Bloch K.D., Moskowitz M.A., Bevan J.A., Fishman M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 377:1995;196-197.
75. Milner P., Kirkpatrick K.A., Ralevic V., et al. Endothelial cells cultured from human umbilical vein release ATP, substance P and acetylcholine in response to increased flow. Proc R Soc Lond (Biol). 241:1990;245-248.
76. Kramer H.F., Glanzer K., Meyer-Lehnert H., Mohaupt M., Predel H.G. Kinin- and non-kinin-mediated interactions of converting-enzyme inhibitors with vasoactive hormones. J Cardiovasc Pharmacol. 15:(suppl 6):1990;S91-S98.
77. Scherf H., Pietsch R., Landsberg G., Kramer H.J., Düsing R. Converting enzyme inhibitor ramipril stimulates prostacyclin synthesis by isolated rat aorta: evidence for a kinin-dependent mechanism. Klin Wochenschr. 64:1986;742-745.
78. Shiota N., Miyazaki M., Okunishi H. Increase of angiotensin converting enzyme gene expression in the hypertensive aorta. Hypertension. 20:1992;168-174.
79. Danckwardt L., Schimuzu I., Bönner G., Rettig R., Unger T. Converting enzyme inhibition in kinin-deficient brown Norway rats. Hypertension. 16:1990;429-435.
80. Bao G., Gohlke P., Quadri F., Unger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension. 20:1992;74-79.
81. Bao G., Gohlke P., Unger T. Role of bradykinin in chronic antihypertensive action of ramipril in different hypertension models. J Cardiovasc Pharmacol. 20:(suppl 9):1992;S96-S99.
82. Bönner G. The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors. Drugs. 54:(Suppl 5):1997;23-30.
83. Gainer J.V., Morrow J.D., Loveland A., King D.J., Brown N.J. Effect of bradykinin receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 339:1998;1285-1292.
84. Arnal J.F., Warin L., Michel J.B. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest. 90:1992;647-652.
85. Young R.H., Ding Y.A., Lee Y.M., Yen M.H. Cilazapril reverses endothelium-dependent vasodilator response to acetylcholine in mesenteric artery from spontaneously hypertensive rats. Am J Hypertens. 8:1995;928-933.
86. Küng C.F., Lüscher T.F. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension. 25:1995;194-200.
87. Calver A., Collier J., Moncada S., Vallance P. Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens. 10:(9):1992;1025-1031.
88. Forte P., Copland M., Smith L.M., et al. Basal nitric oxide synthesis in essential hypertension. The Lancet. 349:1997;837-842.
89. Vaziri N.D., Ni Z., Oveisi F. Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension. 31:1998;1248-1254.
90. Chou T.-C., Yen A.-H., Li C.-Y., Ding Y.-A. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension. 31:1998;643-648.
91. Cosentino F., Patton S., d'Uscio L.V., et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest. 101:(7):1998;1530-1537.
92. Grunfeld S., Hamilton C.A., Mesaros S., et al. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension. 26:(part 1):1995;854-857.
93. Shirasaki Y., Kolm P., Nickols A., Lee T.J.-F. Endothelial regulation of cyclic GMP and vascular responses in hypertension. J Pharmacol Exper Ther. 245:(1):1988;53-58.
94. Hayakawa H, Coffee K, Raij L. Nitric oxide activity is enhanced in the vasculature and renal medulla of spontaneously hypertensive rats but fails to control hypertension. J Am Soc Nephrol 1996;7:1562 [abstract].
95. McIntyre M., Brosnan M.J., Hamilton C.A., et al. Nitric oxide and superoxide balance in a model of genetic hypertension. J Hypertens. 15:(N0 12):1997;1543-1544.
96. Bouloumie A., Bauersachs J., Linz W., et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension. 30:1997;934-941.
97. Bauersachs J., Bouloumie A., Mülsch A., et al. Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. Cardiovasc Res. 37:1998;772-779.
98. Nava E., Farre A.L., Moreno C., et al. Alterations to the nitric oxide pathway in the spontaneously hypertensive rat. J Hypertens. 16:1998;609-616.
99. Tschudi M.R., Mesaros S., Lüscher T., Malinski T. Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Hypertension. 27:1996;32-35.
100. Nava E., Noll G., Lüscher T. Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation. 91:1995;3210-3213.
101. Matsuoka H., Nakata M., Kohno K., et al. Chronic L-arginine adminstration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension. 27:1996;14-18.
102. Crabos M., Coste P., Paccalin M., et al. Reduced basal NO-mediated dilation and decreased endothelial NO-synthase expression in coronary vessels of spontaneously hypertensive rats. J Mol Cell Cardiol. 29:1997;55-65.
103. Clozel M., Kuhn H., Hefti F. Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension. 16:1990;532-540.
104. Rubanyi G.M., Hauser K., Graser T. Effect of cilazapril and indomethazin on endothelial dysfunction in aortae of endothelial function in hypertensive rats hypertensive rats. J Cardiovasc Pharmacol. 22:(suppl 5):1993;S23-S30.
105. Kähönen M., Makynen H., Wu X., Arvola P., Pörsti I. Endothelial function in endothelial function in endothelial function in spontaneously hypertensive rats. Br J Pharmacol. 115:1995;859-867.
106. Gohlke P., Lamberty V., Kuwer I., et al. Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3′,5′-monophosphate. Hypertension. 2:1993;682-687.
107. Morawietz H., Rohrbach S., Darmer D., Hakim K., Zerkowski H.R., Holtz J. Angiotensin converting enzyme inhibitor treatment upregulates the expression of endothelial nitric oxide synthase in human atrial myocardium. Circulation. 94:(8):1996;3047. [abstract].
108. Ravichandran L.V., Johns R.A. Up-regulation of endothelial nitric oxide synthase expression by cyclic guanosine 3′, 5′-monophosphate. FEBS Lett. 374:1995;295-298.
109. Wiemer G., Popp R., Schölkens B.A., Gögelein H. Enhancement of cytosolic calcium, prostacyclin and nitric oxide by bradykinin and the ACE inhibitor ramiprilat in porcine brain capillary endothelial cells. Brain Res. 638:1994;261-266.
110. Hoffmann G., Pietsch R., Göbel B.O., et al. Converting enzyme inhibition and vascular prostacyclin synthesis: effect of kinin receptor antagonism. Eur J Pharmacol. 178:1990;70-83.
111. Schröder H., Schrör K. Prostacyclin-dependent cyclic AMP formation in endothelial cells. Naunyn-Schmiedeberg's Arch Pharmacol. 347:1993;101-104.
112. Lückhoff A., Mülsch A., Busse R. cAMP attenuates autacoid release from endothelial cells: relation to internal calcium. Am J Physiol. 27:1990;H960-H966.
113. Brock T.A., Dennis P.A., Griendling K.K., Diehl T.S., Davies P.F. GTP gamma S loading of endothelial cells stimulates phospholipase C and uncouples ATP receptors. Am J Physiol. 255:1988;C667-C673.
114. Buchan K.W., Martin W. Modulation of agonist-induced calcium mobilisation in bovine aortic endothelial cells by phorbol myristate acetate and cyclic AMP but not cyclic GMP. Br J Pharmacol. 104:(2):1991;361-366.
115. Graier F., Groschner K., Schmidt K., Kukowetz W.R. Increases in endothelial cyclic AMP levels amplify agonist-induced formation of endothelium-derived factor (EDRF). Biochem J. 288:1992;345-349.
116. Zhang X., Miskimins R. Binding at an NF-1 site is modulated by cyclic AMP-dependent activation of myelin basic protein gene expression. J Neurochem. 60/6:1993;2010-2017.
117. Zhang R., Min W., Sesse W.C. Functional analysis of human endothelial nitric oxide synthase promotor. J Biol Chem. 270:1995;2515320-2515326.
118. Belhassen L., Kelly R.A., Smith T.W., Balligand J.-L. Nitric oxide synthase (NOS 3) and contractile responsiveness to adrenergic and cholinergic agonists in the heart: regulation of NOS 3 transcription in vitro and in vivo by cyclic adenosine monophoshate in rat cardiac myocytes. J Clin Invest. 97:1996;1908-1915.
119. Belhassen L., Feron O., Kaye D.M.K., Michel T., Kelly R.A. Regulation by cAMP of post-translational processing and subcellular targeting of endothelial nitric-oxide synthase (type 3) in cardiac myocytes. J Biol Chem. 272:1997;11198-11204.
120. Minor R.L., Myers P.R., Guerra R. Jr., Bates J.N., Harrison D.G. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest. 86:1990;2109-2116.
121. Cooke J.P., Singer A.H., Tsao P., et al. Antiatherogenic effects of L-arginine in the hypercholesterolaemic rabbit. J Clin Invest. 90:1992;1168-1172.
122. Kanazawa K., Kawashima S., Mikami S., et al. Endothelial constitutive nitric oxide synthase protein and mRNA increased in rabbit atherosclerotic aorta despite impaired endothelium-dependent vascular relaxation. Am J Pathol. 148:1996;1949-1956.
123. Cayatte A.J., Palacino J.J., Horten K., Cohen R.A. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolaemic rabbits. Arterioscler Thromb. 14:1994;753-759.
124. Quyyumi A.A., Daka N., Mulcahy D., et al. Nitric oxide activation in the atherosclerotic human coronary circulation. J Am Coll Cardiol. 29:1997;308-317.
125. Drexler H., Zeiher A., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. The Lancet. 338:1991;1546-1550.
126. Chauhan A., More R.S., Mullins P.A., et al. Aging-associated dysfunction in humans is reversed by L-arginine. J Am Coll Cardiol. 28:1996;1796-1804.
127. Creager M.A., Girerd X.J., Gallagher S.H., et al. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolaemic humans. J Clin Invest. 90:1992;1248-1253.
128. Clarkson P., Adams M.R., Powe A.J., et al. Oral L-Arginine improves endothelium-dependent dilation in hypercholesterolaemic young adults. J Clin Invest. 97:1996;1989-1994.
129. Wilcox J.N., Subramanian R.R., Sundell C.L., et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 17:1997;2479-2488.
130. Oemar B.S., Tschudi M.R., Godoy N., et al. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 97:1998;2494-2498.
131. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolaemia increases endothelial superoxide anion production. J Clin Invest. 91:1993;2546-2551.
132. Pritchard K.A. Jr., Groszek L., Smalley D.M., et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res. 77:1995;510-518.
133. Schuh J.R., Blehm D.J., Friedrich D.E., McMahon E.G., Blaine E.H. Differential effects of renin angiotensin system blockade on atherosclerosis on cholesterol-fed rabbits. J Clin Invest. 91:1993;1453-1458.
134. Riezebos J., Vleeming W., Beems R.B., et al. Comparison of the antiatherogenic effect of isradipine and ramipril in cholesterol-fed rabbits: I. effect on progression of atherosclerosis and endothelial dysfunction. J Cardiovasc Pharmacol. 23:1994;415-423.
135. Riezebos J., Vleeming W., Beems R.B., et al. Comparison of the antiatherogenic effect of isradipine and ramipril in cholesterol-fed rabbits: II. effect on regression of atherosclerosis and restoration of endothelial function. J Cardiovasc Pharmacol. 23:1994;424-431.
136. Becker R.H.A., Wiemer G., Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol. 18:(suppl 2):1991;S10-S15.
137. Chobanian A.V., Haudenschild C.C., Nickerson C., Drago R. Antiatherogenic effect of captopril in the watanabe heritable hyperlipidemic rabbit. Hypertension. 15:1990;327-331.
138. Chobanian A.V., Haudenschild C.C., Nickerson C., Hope S. Trandolapril inhibits atherosclerosis in the watanbe heritable hyperlipidemic rabbit. Hypertension. 20:1992;473-477.
139. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 74:1994;1141-1148.
140. Diet F.D., Tratt R.E., Berry G.J., et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 94:1996;2756-2757.
141. Farhy R.D., Carretero O.A., Ho K.L., Scicli G. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res. 72:1993;1201-1210.
142. Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 83:1989;1774-1777.
143. Berkenboom G., Langer I., Carpentier Y., Grosfils K., Fontaine J. Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins. Hypertension. 30:(part1):1997;371-376.
144. Hayek T., Attias J., Smith J., Breslow J.L., Keidar S. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 31:1998;540-544.
145. Hayek T, Keidar S, Mei Y, Oiknine J, Breslow J. Effect of angiotensin converting enzyme inhibitors on LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Circulation 1995;92:2998 [abstract].
146. Mancini G.B.J.M., Henry G.C., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation. 94:1996;258-265.
147. Wall T., Linseman D., Shebuski R., Hartman J. Ramiprilat and des-arg bradykinin attenuate hypoxix injury in isolated cardiac myocyte. FASEB J. 7:1993;691.
148. Martorana P.A., Kettenbach B., Breipohl G., Linz W., Schölkens B.A. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol. 182:1990;395-396.
149. Hartman J.C., Wall T.M., Hullinger T.G., Shebuski R.J. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol. 21:1993;996-1003.
150. Blais C., Drapeau G., Paymond P., et al. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am J Physiol. 273:(Heart Circ Physiol. 42):1997;H2263-H2271.
151. Baumgarten C.R., Linz W., Kunkel G., Schölkens B.A., Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol. 108:1993;293-295.
152. Dendorfer A., Wolfrum S., Wellhöner P., Korsman K., Dominiak P. Intravascular and interstitial degradation of bradykinin in isolated perfused rat heart. Br J Pharmacol. 122:1997;1179-1187.
153. Campbell D.J., Kladis A., Duncan A.-M. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension. 21:1993;155-165.
154. Nolly H., Carbini L.A., Scicli G., Carretero O.A., Scicli A.G. A local kallikrein-kinin system is present in rat hearts. Hypertension. 23:(part 2):1994;919-923.
155. Hashimoto K., Hirose M., Furukawa H., Kimura E. changes in hemodynamics and bradykinin concentration in coronary sinus blood in experimental coronary occlusion. Jap Heart J. 18:1977;679-689.
156. 9-bradykinin release following reperfusion of the ischaemic rat heart. Br J Pharmacol. 115:1995;476-478.
157. Linz W., Wiemer G., Schölkens B.A. Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Am J Cardiol. 80:(3A):1997;118A-123A.
158. 2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension. 30:(part 2):1997;735-740.
159. 2 receptor activation in human heart. J Am Coll Cardiol. 29:1997;1599-1606.
160. 2 receptor-NO pathway and protein synthesis. Br J Pharmacol. 125:1988;556-562.
161. Node K., Kitakaze M., Kosaka H., et al. Increased release of NO during ischaemia reduces myocardial contractility and improves metabolic dysfunction. Circulation. 93:1996;356-364.
162. Node K., Kitakaze M., Sato H., et al. Increased release of nitric oxide in ischaemic hearts after exercise in patients with effort angina. J Am Coll Cardiol. 32:1998;63-68.
163. Rudic R., Shesely E.G., Maeda N., et al. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest. 101:1998;731-736.
164. Nasa Y., Toyoshima H., Ohaku H., et al. Impairment of cGMP- and cAMP-mediated vasorelaxations in rats with chronic heart failure. Am J Physiol. 271:(Heart Circ Physiol. 40):1996;H2228-H2237.
165. Baggia S., Perkins K., Greenberg B. Endothelium-dependent relaxation is not uniformly impaired in chronic heart failure. J Cardiovasc Pharmacol. 29:1997;389-396.
166. Mulder P., Devaux B., Richard V., et al. Early versus delayed angiotensin-converting enzyme inhibition in experimental chronic heart failure. Effects on survival, hemodynamics, and cardiovascular remodeling. Circulation. 95:1997;1314-1319.
167. Pfeffer M.A., Greaves S.C., Arnold M.O., et al. for the Healing and Early Afterload Reducing Therapy (HEART) Trial Investigators. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The Healing and Early Afterload Reducing Therapy Trial. Circulation. 95:1997;2643-2651.
168. Linz W., Schölkens B.A., Wohlfart P., Wiemer G. Late ACE inhibitor treatment protects old spontaneously hypertensive rats from cardiovascular death. Am J Hypertens. 11:1998;12A-13A.
169. Ritchie R.H., Schiebinger R.J., Lapointe M.C., March J.D. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol. 275:(Heart Circ Physiol 44):1998;H1370-H1374.
170. Liu Y.-H., Yang X.-P., Sharov V.G., et al. Effects of
171. 1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res. 39:1998;401-412.
172. 2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 105:1992;771-772.
173. Stauss H.M., Zhu Y.C., Redlich T., et al. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J Cardiovasc Risk. 1:(3):1994;255-262.
174. Wollert K.C., Studer R., Doerfer K., et al. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation. 95:1997;1910-1917.
175. Waeber B., Brunner H.R. Cardiovascular hypertrophy: Role of angiotensin II and bradykinin. J Cardiovasc Pharmacol. 27:(Suppl 2):1996;S36-S40.
176. Ritchie R.H., Marsh J.D., Lancaster W.D., Diglio C.A., Schiebinger R.J. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. Hypertension. 31:(part 1):1998;39-44.
177. Cheng C.-P., Onishi K., Ohte N., Suzuki M., Little W. Functional effects of endogenous bradykinin in congestive heart failure. J Am Coll Cardiol. 31:1998;1679-1686.
178. Takemoto M., Egashira K., Tomita H., et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade. Effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension. 30:1997;1621-1627.
179. Zhang X., Xie Y.-W., Nasjletti A., et al. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation. 95:1997;176-182.
180. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389.
181. Suto N., Mikuniya A., Okubo T. et al., Nitric oxide modulates cardiac contractility and oxygen consumption without changing contractile efficiency. Am J Physiol 1998;275 (Heart Circ Res 44):H41-H9.
182. Suto N., Mikuniya A., Okubo T. et al., Nitric oxide modulates cardiac contractility and oxygen consumption without changing contractile efficiency. Am J Physiol 1998;275 (Heart Circ Res 44):H41-H9.
183. Shah A.M. Paracrine modulation of heart cell function by endothelial cells. Cardiovasc Res. 31:1996;847-867.
184. Shen W., Hintze T.H., Wolin M.S. Nitric oxide: an important signaling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. Circulation. 92:1995;1086-1095.